Founder and CEO of Nemesis Health; physician-epidemiologist and biostatistician focused on large-scale, transparent oncology evidence generation. Her work bridges OHDSI methods, federated cancer networks and the practical use of real-world data to answer clinical questions that trials cannot cover alone.

Chief Science Officer of Nemesis Health and a principal investigator in OHDSI. He is one of the architects behind the OMOP common data model and standardized vocabularies that make reproducible, large-scale observational research possible across institutions.

Professor of personalised cancer medicine at the University of Helsinki and HUS Comprehensive Cancer Center. His work connects precision oncology, clinical practice and health-data infrastructure; within FALCON, he brings lessons from large-scale metastatic lung cancer evidence generation.

Medical oncologist at Antwerp University Hospital with a focus on trustworthy real-world evidence to close clinical knowledge gaps. She leads the UZA Data Access Committee, contributes to FALCON, DARWIN EU and FHIN, and helps connect clinical, data-science and oncology communities through OHDSI Belgium and the BSMO Digital Oncology task force.

Director Data & Innovation at AZ Delta and founder/director of the Federated Health Innovation Network. He leads RADar, the hospital innovation centre, and works on predictive AI, data-driven care pathways and federated collaboration models for healthcare data reuse.

Engineer and mathematician with more than 20 years of experience in digitisation of the social and public health sector. Since 2020, he has advised the Belgian Minister of Social Affairs and Public Health on digital health, health data, privacy, the European Health Data Space and AI legislation.

Medical oncologist at Dana-Farber Cancer Institute and faculty member at Harvard Medical School, where he serves as Clinical and Translational Director of the Immunotherapy Toxicity Program. His work spans cancer drug development, immunotherapy and the complementary role of evidence from clinical practice.

Senior Director and EMEA Therapeutic Area Lead for Oncology at Johnson & Johnson Innovative Medicine. She brings an industry perspective on how targeted therapies, precision medicine and real-world evidence can improve bladder cancer outcomes and patient-centred decision-making.

Health economics and payer evidence lead. She brings a payer and market-access perspective to the discussion: which real-world evidence is convincing enough to influence reimbursement, policy, adoption and equitable access to innovation.

Head of the Integrated Cancer Center Ghent and guest professor at the University of Antwerp. His research focuses on urogenital and gynaecological malignancies, with a strong track record in clinical and translational oncology, including practice-changing bladder cancer trials.

Medical Director of Oncology within UMC Utrecht and chair of the ESMO taskforce on Real World Data and Digital Health. Founder and chair of the Dutch Prospective Colorectal Cancer Cohort (PLCRC), which includes >24,000 patients and >50 ongoing substudies.

Executive Director and Global Head of Late Data Science and Real World Evidence at AstraZeneca. He leads multidisciplinary teams using real-world data, advanced analytics, machine learning and AI to generate evidence for clinical development, regulatory decision-making and patient access.